1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Aurora Spine Corporation

Aurora Spine Corporation

ASG.V
Aurora Spine CorporationCA flagToronto Stock Exchange Ventures
0.24
CAD
- -
- -
18.74MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.12
0.19
0.21
0.17
0.21
0.24
0.16
0.18
0.22
0.21
0.23
- -
0.24
Basic EPS, GAAP
-0.22
-0.35
-0.11
-0.05
-0.06
- -
-0.03
- -
-0.04
-0.02
-0.02
-0.01
- -
-0.01
Free Cash Flow per Basic Share
-0.21
-0.46
-0.15
-0.05
-0.04
- -
-0.01
- -
-0.05
-0.04
-0.02
0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.22
-0.55
-0.57
-0.51
0.03
0.05
0.01
0.03
0.04
0.02
0.03
0.01
- -
- -
Tangible Book Value per Share
0.01
0.15
0.17
0.1
0.04
0.05
0.02
0.04
0.08
0.05
0.06
0.05
- -
0.04
Basic Weighted Avg Shares
7
22
26
32
35
42
46
55
59
67
71
78
- -
78
Sales/Revenue/Turnover
- -
3
5
7
6
9
11
9
11
15
15
18
18
18
Operating Margin (%)
- -
-289.79
-63.15
-23.95
-33.78
1.05
-9.68
-13.46
-24.19
-9.03
-10.3
-2.76
-1.8
-1.8
Depreciation Expense
- -
- -
1
1
1
1
- -
1
1
1
1
1
1
1
Net Income, GAAP
-1
-8
-3
-2
-2
- -
-1
- -
-2
-2
-2
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-289.79
-59.51
-24.85
-37.41
-0.79
-11.25
-2.68
-22.37
-10.09
-11.57
-5.71
-3.98
-3.98
Working Capital
- -
- -
2
2
2
3
2
4
6
4
5
5
4
4
LT Debt
- -
- -
- -
- -
2
2
2
2
2
3
3
3
3
3
Total Equity
- -
3
5
3
2
3
2
3
6
4
5
4
4
4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
-4.54
-95.94
-19.01
-110.56
-83.01
-111.83
-72.6
-129.95
-129.95

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
3
3
3
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
78
78
Market Capitalization
18
16
15

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
9
9
8
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
3
3
3
Inventories
4
4
3
Total Current Liabilities
4
5
3
Payables & Accruals
4
4
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.57%
7.93%
-13.29%
Free Cash Flow
35.42%
172.03%
-11.01%
Net Income, GAAP
237.64%
164.95%
-27.08%
Sales/Revenue/Turnover
16.36%
17.24%
4.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
3
4
4
4
15
2024
4
4
5
5
18
2025
4
4
4
5
18

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.01
-0.01
- -
- -
-0.02
2024
- -
- -
- -
-0.01
-0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Trent J. Northcutt
Full Time Employees
13
Sector
Healthcare
Industry
Medical - Devices
Address
20 Holly Street Toronto ON Canada M4S 3B1
IPO Date
Sep 13, 2013
Website
aurora-spine.com
Similar Companies
PAVmed Inc. (PAVM)
PetVivo Holdings, Inc. (PETVW)
Anika Therapeutics, Inc. (ANIK)
Helius Medical Technologies, Inc. (HSM.TO)
Kelyniam Global, Inc. (KLYG)
CellaVision AB (publ) (CEVI.ST)
Business
Aurora Spine Corporation (TSXV:ASG), through its subsidiary Aurora Spine Inc., develops, manufactures and distributes minimally invasive spinal implants, surgical tools, biologics and interventional pain solutions targeting degenerative disc disease, spinal fusion and sacroiliac joint dysfunction; its core products include interspinous process lumbar fusion devices such as ZIP, ZIP ULTRA, ZIP LP and ZIP-51, Ti-Coated polyether ether ketone interbody cages, sterile-packed titanium plasma spray coated spinal fusion implants, lumbar interbody products including EOS, VOX, Echo, Echo SD and EchoXL, cervical products such as Discovery, anterior lumbar interbody fusion devices like SOLO, posterior sacroiliac fusion systems including SiLO, non-fusion interspinous implants such as Zip Flex, surgical tools encompassing anterior and posterior disc prep systems and Compass 4D Retractor System, and biologics comprising ZIP Graft, Amniopur, TURBO FUSE Fiber Putty, OSTEO GRAFT DBM Putty and OSTEO BRIDGE Sponge Strips. The company, founded in 2012 and headquartered at 20 Holly Street, Suite 300 in Toronto, Ontario, Canada, with design, development and manufacturing operations based in Carlsbad, California, primarily serves orthopedic surgeons, neurosurgeons and pain management specialists worldwide through a focus on patient-centric, regenerative technologies for cervical, thoracolumbar and SI joint applications. In October 2025, Aurora Spine launched Aurora Biologics, a new division offering comprehensive allograft solutions to enhance spinal fusion outcomes and integrate with existing portfolios including ZIP, Hydra A.E.R.O., DEXA and SiLO systems, positioning the company as a vertically integrated provider; earlier in 2025, it secured FDA 510(k) clearance for the Aero facet fusion system, completed enrollment in the Refine study for lumbar interlaminar fusion, and appointed Matt Paxton as executive vice president of sales and Katelyn Sims as area vice president of commercialization and key accounts.

Company News

APIChat

  • globenewswire.com

    Aurora Spine Corporation Schedules Release of First Quarter Fiscal 2026 Financial Results

  • globenewswire.com

    Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants